Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
U.S. State
PPTA supports patient access to all medically appropriate plasma protein therapies, which because of important clinical and manufacturing differences, an individual patient may tolerate or respond to one therapy better than another in the same class.
All
Access to care
U.S. State
PPTA supports patient access to all medically appropriate plasma protein therapies, which because of important clinical and manufacturing differences, an individual patient may tolerate or respond to one therapy better than another in the same class.
All
Access to care
U.S. Federal
PPTA prepares policy documents (such as issue briefs, statements, backgrounds, and white papers) on a variety of policy topics that are relevant to protecting patient access and are important to the association and its members.
All
Access to care
U.S. Federal
PPTA prepares policy documents (such as issue briefs, statements, backgrounds, and white papers) on a variety of policy topics that are relevant to protecting patient access and are important to the association and its members.
All
Access to care
Rare diseases
Plasma protein therapies replace missing or deficient proteins that allow individuals to lead healthy and more productive lives. The patients that rely on these therapies generally require regular infusions or injections throughout their lives. The diseases and conditions treated by plasma protein therapies are considered rare diseases because they affect a relatively small percent of the population. Most are genetic, chronic conditions.
All
Plasma therapies
Rare diseases
Plasma protein therapies replace missing or deficient proteins that allow individuals to lead healthy and more productive lives. The patients that rely on these therapies generally require regular infusions or injections throughout their lives. The diseases and conditions treated by plasma protein therapies are considered rare diseases because they affect a relatively small percent of the population. Most are genetic, chronic conditions.
All
Plasma therapies
North America Data program
In collaboration with industry regulators and stakeholders, PPTA has developed a system that we believe is the best way to present the distribution of core plasma protein therapies in North America.
All
Plasma therapies
North America Data program
In collaboration with industry regulators and stakeholders, PPTA has developed a system that we believe is the best way to present the distribution of core plasma protein therapies in North America.
All
Plasma therapies
No results found